Inclusion Criteria:

1. Patients age 18 years of age or older with CML-AP, CML-BP or Philadelphia
chromosome-positive acute myeloid leukemia defined as follows: CML-AP is defined by
the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), >/= 20%
basophils in PB or BM, >/= 30% blasts plus promyelocytes (with blasts <30%) in PB or
BM, <100 x10(9)/L platelets unrelated to therapy, or by clonal cytogenetics evolution
(i.e., the presence of cytogenetic abnormalities other than the Philadelphia
chromosome); CML-BP is defined by the presence of >/= 30% blasts in the bone marrow
and/or peripheral blood or the presence of extramedullary disease.

2. Patients are eligible whether they have received or not prior TKI therapy. For the
phase I portion of the study, patients who had received prior therapy with dasatinib
should have been able to tolerate the dose equivalent to the starting dose of
dasatinib in the dose level at which the patient is being entered. Patients who
previously received dasatinib but never at the dose being proposed are eligible
provided they tolerated the maximum dose they were prescribed with no grade 3-4
toxicity not responding to optimal management.

3. ECOG performance status 0-3.

4. Men and women of childbearing potential should practice effective methods of
contraception. Men and women of childbearing potential are defined as: a male that
has not been surgically sterilized or a female that has not been amenorrheic for at
least 12 consecutive months or that has not been surgically sterilized. Patients must
use birth control during the study and for 3 months after the last dose of study drug
if they are sexually active.

5. Women of childbearing potential must have a pregnancy test at screening.

6. Signed informed consent.

7. Patients must have been off all prior therapy for CML for 2 weeks prior to start of
study therapy and recovered from the toxic effects of that therapy. Exceptions to
these are hydroxyurea and TKIs (including but not limited to imatinib, nilotinib, and
bosutinib) which should be discontinued >/= 24 hrs prior to the start of therapy.
Patients who are receiving dasatinib prior to enrollment do not have to discontinue
this agent prior to start of study therapy.

8. Adequate organ function: Serum creatinine /=60
mL/min; Total bilirubin hemolysis); Alanine aminotransferase (ALT) leukemic involvement.

Exclusion Criteria:

1. NYHA cardiac class 3-4 heart disease.

2. Cardiac disease including: Uncontrolled angina within 3 months. Diagnosed or
suspected congenital long QT syndrome; Any history of clinically significant
ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or
Torsades de pointes); Prolonged QTc interval on pre-entry electrocardiogram (> 470
msec) on both the Fridericia and Bazett's correction; Uncontrolled hypertension
(defined for this protocol as sustained systolic BP >/=150 and diastolic >/=100);
Patients currently taking drugs that are generally accepted to have a risk of causing
Torsades de Pointes.

3. Serious uncontrolled medical disorder or uncontrolled active systemic infection or
current unstable or decompensated respiratory or cardiac conditions which makes it
undesirable or unsafe for the patient to participate in the study.

4. Patients with known, clinically significant pericardial or pleural effusion.

5. History of significant bleeding disorder unrelated to cancer, including diagnosed
congenital bleeding disorders (e.g., von Willebrand's disease), or diagnosed acquired
bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies).

6. Subject is receiving potent inhibitors of CYP3A4; for such medications, a wash-out
period of >/= 7 days is required prior to starting dasatinib unless discontinuation
or substitution of such an inhibitor is not in the best interest of the patient as
determined by the investigator. These include the following medications:
itraconazole, ketoconazole, miconazole, voriconazole; amprenavir, atazanavir,
fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin, clarithromycin,
diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone, nicardipine,
propofol, quinidine, telithromycin. In instances where use of these agents is felt to
be required for the best management of the patients, inclusion of such a patients
should be discussed with PI and the rationale documented.

7. Females who are pregnant or are currently breastfeeding.

8. Patients that are eligible (including having available donor) and willing to receive
an allogeneic stem cell transplant within 4 weeks.